Cancer Institute appoints Dan Mulkerin to a new executive role
New Medical Director at Wilmot Cancer Institute to Lead Regional Expansion
Dan Mulkerin, a seasoned oncology leader, has been promoted to Medical Director and Associate Chief Medical Officer at Wilmot Cancer Institute. In his new role, Mulkerin will oversee quality improvements, clinical IT infrastructure, pharmacy interactions, and patient flow, among other responsibilities.
Mulkerin's first major task will be to lead the opening of Wilmot Cancer Institute's 14th regional location in Webster. This new facility is part of a broader strategy to bring high-quality cancer care closer to home for patients. With Mulkerin at the helm, the Webster location aims to enhance education opportunities for Wilmot providers and patients, extend collaborative research throughout the region, and offer a broad array of clinical services to support Wilmot's research initiatives.
Mulkerin's focus is on offering a consistent experience to patients across all Wilmot locations, in line with the spirit of Meliora. He aims to improve the consistency of the patient experience from initial diagnosis throughout their treatment, regardless of the location chosen.
Prior to joining Wilmot, Mulkerin worked in a similar role at the University of Wisconsin Carbone Cancer Center, where he reorganized clinical operations and created a more cohesive program that was disseminated across its Midwest regional network.
Mulkerin joined Wilmot Cancer Institute two years ago as Associate Director, Regional Operations and Vice Chair, Regional Operations for the Department of Medicine. In his new dual role, he will report to the Cancer Center Director, Jonathan Friedberg, M.D., M.M.Sc, as Medical Director and to Strong Memorial Hospital's Chief Medical Officer, Michael Apostolakos, M.D., as Associate Chief Medical Officer.
The promotion took effect on September 1, 2023. Mulkerin is particularly proud of the new Wilmot-Webster location and its ability to deliver high-quality cancer care closer to home for patients. The creation of this new position is in line with NCI-designated peer institutions across the country.
The promotion aims to provide unparalleled access to cutting-edge care in Upstate New York by acknowledging the strengths of its providers and furthering integration across departments when it comes to patient care. More than half of Wilmot's patients receive their care at regional locations, and Mulkerin has extended the benefits of a university cancer center into these communities. Additionally, under Mulkerin's leadership, more faculty members were recruited to expand the capacity to care for patients at Wilmot.
As Mulkerin continues to treat patients at the cancer center, he looks forward to driving innovations in clinical care delivery, fostering collaborative care networks, and ensuring physicians’ input shapes policies and practices. The new Wilmot-Webster location is just the beginning of Mulkerin's vision for a more connected, patient-centric Wilmot Cancer Institute.
[1] Information based on standard expectations for similar leadership roles at oncology centers like Wilmot Cancer Institute.
- Dan Mulkerin, in his new position as Medical Director at Wilmot Cancer Institute, will aim to leverage science and medical-conditions research to enhance the quality of patient care, focusing on cancer treatments, and facilitate health-and-wellness programs for patients across all locations.
- As part of a broader strategy to bring high-quality cancer care closer to home for patients, Mulkerin's vision for Wilmot Cancer Institute includes extending collaborative research throughout the region, fostering education opportunities for providers and patients, and offering a diverse range of clinical services to support research initiatives and improve patient care experiences, reflecting the spirit of Meliora.
